
GLP-1 Patches for Weight Loss: Do They Actually Work? (2026 Fact Check)
GLP-1 patches sold online don't contain semaglutide or tirzepatide — they're herbal supplements. Here's what the science says and what actually works.
12 articles tagged #semaglutide.

GLP-1 patches sold online don't contain semaglutide or tirzepatide — they're herbal supplements. Here's what the science says and what actually works.

Clinical trials show 15–17% body weight loss with semaglutide over 68 weeks. Here's what to expect month by month, backed by data from the STEP trials.

A practical guide to the most common GLP-1 side effects — nausea, GI issues, hair loss, and more — with evidence-based strategies to manage them and red flags that mean you should call your doctor.

Certain foods can make GLP-1 side effects dramatically worse. Learn which foods to avoid on Ozempic, Wegovy, and Zepbound — plus what to eat instead for better tolerance and results.

Tirzepatide produces 20.2% weight loss vs semaglutide's 13.7% in head-to-head trials, but costs $50–$150/mo more. Full comparison of efficacy, side effects, cost, and which one to choose in 2026.

Oral Wegovy (semaglutide 25mg pill) is now FDA-approved alongside the original weekly injection. We compare weight loss data, side effects, dosing convenience, cost, and who should pick which form.

Ozempic and Wegovy contain the exact same active ingredient — semaglutide — but they're approved for different conditions, come in different doses, and are priced differently. Here's what actually matters when choosing between them.

The two most prescribed GLP-1 weight loss drugs go head to head — clinical results, pricing, side effects, insurance, and which one is right for you.

Beyond Wegovy and Zepbound, a new generation of obesity drugs is racing toward FDA approval. CagriSema, MariTide (monthly injection), survodutide, and more — here's every drug in the pipeline with clinical data.

Starting a GLP-1? Here's a realistic week-by-week breakdown of what happens — from the initial consultation through your first dose escalation.

The FDA ended the semaglutide shortage in February 2025, upending the compounded GLP-1 market. Here's what changed, what's legal, and how to choose.

Everything you need to know about GLP-1 receptor agonists — how they work, what the clinical trials show, side effects, eligibility, and how to choose a provider.